m-TOR inhibitors: What role in liver transplantation? Toshiyasu Kawahara, Sonal Asthana, Norman M. Kneteman  Journal of Hepatology  Volume 55, Issue 6, Pages 1441-1451 (December 2011) DOI: 10.1016/j.jhep.2011.06.015 Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Structures of sirolimus and everolimus. Journal of Hepatology 2011 55, 1441-1451DOI: (10.1016/j.jhep.2011.06.015) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 2 An overview of the m-TOR signaling pathway and relative activities. Journal of Hepatology 2011 55, 1441-1451DOI: (10.1016/j.jhep.2011.06.015) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Glomerular filtration rate (GFR) either with everolimus or cyclosporine A after liver transplantation. Significantly improved GFR was observed in the everolimus group from 1month after liver transplantation with early withdrawal of cyclosporine A. [28]. Journal of Hepatology 2011 55, 1441-1451DOI: (10.1016/j.jhep.2011.06.015) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Creatinine clearance with everolimus or cyclosporine A after liver transplantation. Stable, but not improved renal function was observed after conversion from a calcineurin inhibitor to everolimus a relatively long mean time post-liver transplant (>3years) [29]. Journal of Hepatology 2011 55, 1441-1451DOI: (10.1016/j.jhep.2011.06.015) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions